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ABSTRACT Inflammatory caspases-1, -4, and -5 play critical roles in mediating the innate immune
response to pathogen- and damage-associated molecular patterns. Caspase-1 produces the cytokine
interleukin-1β (IL-1β), while caspases-4 and -5 activate the NOD-like receptor protein 3 inflammasome
via the non-canonical pathway. Overactivation of these enzymes is associated with an increased risk for
inflammatory diseases such as lupus, psoriasis, and rheumatoid arthritis. Small molecule inhibitors
(SMIs) have been developed to attenuate the production of IL-1β, but unfavorable bioavailability and
toxicity have provided an insurmountable barrier in clinical trials. This work is concerned with
delivering an overview of current progress in the synthetic design of SMIs of the inflammatory caspases.

INTRODUCTION
Caspases-1, -4, and -5 are cysteine-dependent
proteases that have essential roles in phagocytic
cells of the innate immune system. Pathogen- and
damage-associated molecular patterns (PAMPs
and DAMPs) are recognized by the NOD-like
receptor protein 3 (NLRP3) inflammasome,
which is responsible for cleaving the zymogen
pro-caspase-1 into its active tetrameric form.27
Once activated, caspase-1 produces the
inflammatory cytokine interleukin-1β (IL-1β)
from its precursor, which is secreted to recruit
other circulating immune cells into the affected
tissue. The inflammatory cascade is complicated

by the involvement of caspases-4 and -5, which
produce another inflammatory cytokine,
interleukin-1α (IL-1α) and also indirectly activate
pro-caspase-1.1 These enzymes have been
observed to be induced upon sensing pathogenic
species like liposaccharides (LPS); though, like
the canonical pathway, the mechanism of
activation is not fully understood.24
Constitutive activity of the canonical
NLRP3/caspase-1 pathway leads to harmful
pyroptotic responses that are a characteristic of
inflammatory diseases like lupus, psoriasis, and

____________________________________
* cahlers@depaul.edu
Research Completed in Summer 2020

Published by Via Sapientiae, 2021

1

DePaul Discoveries, Vol. 10 [2021], Iss. 1, Art. 13

rheumatoid arthritis. Currently, there are several
protein-based treatments that decrease the effects
of IL-1β, such as anakinra, canakinumab, and
rilonacept.8 These proteins act as IL-1β
antagonists, monoclonal antibodies, and soluble
receptors, respectively (Figure 1). While anakinra
blocks the cytokine’s binding site on the IL-1β
receptor protein, canakinumab is an antibody
treatment that neutralizes IL-1β instead of
competing with it at the binding site. Rilonacept
is a receptor protein designed to bind IL-1β;
however, since it is soluble in blood plasma and
not integrated into the membrane of a leukocyte,
any cytokines lured to this protein do not
contribute to the inflammatory response.
Although effective, these treatments are
expensive to produce and must be administered
via injection due to the harsh environment of the
stomach, which prevents an optimal oral
alternative. Additionally, the half-lives of these
proteins are not ideal. For instance, anakinra
degrades quickly and requires frequent injections,
while the biostability of canakinumab confers a
long half-life that leaves the individual at risk for
infections.4

rather than merely disguising the cytokine’s
effects. Traditionally, potent inhibitors of
caspases have employed an electrophilic
functional group to trap the essential thiolate
residue in the active site. However, SMIs have
since broadened to target allosteric sites as well.
Candidates that demonstrate compatibility with
more than one caspase have also been discovered.
Currently, all SMIs that have reached clinical
trials have failed to pass them.13 Herein, a review
is presented of currently known SMIs of
caspases-1, -4, and -5 with a focus on structural
themes.
INHIBITORS OF CASPASE-1
Most known inhibitors of caspase-1 are
peptidomimetic and bind at the aspartate-specific
active site. The proteolytic residue Cys285 can be
trapped by a carbonylic group in either a
reversible or irreversible manner, stopping the
cleavage of pro-IL-1β. The structure of a
competitive caspase-1 inhibitor can be
generalized as having a core, P4-P2, and prime
side fragment (Figure 2).

The disadvantages of protein-based treatment
methods have made small molecule inhibitors
(SMIs) of the inflammatory caspases attractive
research prospects. This approach directly
decreases the activation and secretion of IL-1β

The core fragment contains an aspartate moiety
that acts as an electrophilic trap for the proteolytic
thiolate. The prime side, which is not present in
all inhibitors, adds additional stabilization in the
active site by anchoring the substrate to the
interior hydrophobic pocket of the enzyme. The

Figure 1. Decreased effects of IL-1β signaling via
protein drugs. Displayed are the three approved
treatments for targeting caspase-activated IL-1β:
blocking the cytokine’s receptor (anakinra),
destroying the cytokine (canakinumab), and luring the
cytokine to a soluble decoy receptor (rilonacept).

Figure 2. General structure of a competitive inhibitor
of caspase-1. The scaffold contains an aspartate
residue (core fragment) with extensions that interact
with the S2-S4 region (P4-P2 fragment) and the interior
hydrophobic pocket (prime side fragment) of caspase1.
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P4-P2 fragment describes the structure of one of
the first-identified reversible inhibitors, AcYVAD-CHO.14 The tyrosine (P4), valine (P3), and
alanine (P2) moieties appear to interact with
caspase-1 through hydrophobic interactions of
the side chains and hydrogen bonds of the
backbone amides. (Figure 3). However, analysis
via X-ray crystallography has demonstrated that
the hydrogen bonds formed by the backbone
amides of the P4-P2 fragment are not required for
binding, prompting designs that involve less
restricted peptidomimetic derivatives.18
A nearly invariable characteristic of all potent
caspase-1 inhibitors is the presence of an
electrophilic warhead. In both reversible and
irreversible inhibition, the side chain of Cys285
undergoes a nucleophilic attack at the carbonylic
carbon of the inhibitor. In reversible inhibition,
the tetrahedral intermediate is momentarily
stabilized by the oxyanion hole until collapsing
and breaking its covalency with the inhibitor. An
analogous intermediate characterizes the
irreversible mode of inhibition. However, since
the SMI is equipped with a leaving group, it can

irreversibly trap the proteolytic cysteine residue
by detaching its prime side.
Two of the first identified inhibitors of caspase-1
are the peptidic aldehydes 1 and 2 (Figure 4).2, 21
These SMIs offer reversible interactions with the
protease that closely resemble the natural
substrate via an aspartate residue at the P1
position, exhibiting Ki values of 0.76 and 0.056
nM, respectively. The aromatic residues at the P4
position are known to interact strongly with
His342 and Pro343, two residues involved in
inhibitor binding.20 Despite significantly
decreasing the levels of IL-1β in rats17, neither of
these SMIs demonstrate an acceptable cellular
permeability in human cells.
Although inhibitors with tetrapeptide motifs like
1 and 2 are highly compatible with the active site
of caspase-1, they are not promising drug
candidates due to poor cell permeability, toxicity,
stability, and selectivity.3 Such a reality has
prompted the design of less restricted
peptidomimetic structures by using these two
inhibitors as the epicenters of optimization. Since
1 and 2 are both potent inhibitors of caspase-1
despite having chemically different amino acid

Figure 3. Peptidomimetic interactions with caspase-1. PyMOL entry 5mtk. Caspase-1 interacts with an inhibitor
through its S1 and S2-S4 regions, displayed in yellow and orange, respectively. The side chain of the putative catalytic
residue Cys285 is showcased. The hydrophobic pocket is displayed in purple.
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Figure 4. Known inhibitors of caspase-1.

residues at the P2 and P3 positions, this suggests
that this part of the inhibitor can be varied to
attain an improved pharmacological profile. The
structure of the pro-drug pralnacasan 3 is one
such variant. The nonpolar cyclic constraints in
the P2 and P3 positions offer increased
bioavailability and stability without affecting its
potency. Indeed, 3 has caused decreased levels of
IL-1β from mononuclear cells of LPS-challenged
mice.22 The drug advanced to late-stage clinical
trials before its candidacy was withdrawn due to
toxicological concerns present in the livers of the
murine test subjects.15
The P2-P3 sites have also been designed with
acyclic components. Succinic acid amides like 4
have shown promising bioavailability in addition
to potent inhibition of caspase-1.5 Like 1-3,
compound 4 has a truncated prime side fragment,
possessing only an ethyl acylal pro-drug

https://via.library.depaul.edu/depaul-disc/vol10/iss1/13

component. The pro-drug form was found to be
essential for bioavailability. The ionization of the
aspartate residue confers an inability to cross the
lipophilic bilayer.
Interestingly, docking studies of 4 revealed that
the succinic acid amide scaffold does not interact
with the S3 region of caspase-1 and instead
prefers to stabilize itself through hydrogen
bonding with the solvent. This finding provided
further evidence that the P2-P3 components of a
caspase-1 inhibitor are not essential for binding
to the enzyme. Thus, they should be adjusted to
optimize the alignment of the aromatic P4
position in the active site. Analogs of 4 that
employed cyclized P2-P3 components were
substantially less potent. Since cyclization of the
analogous positions in 3 did not cause a similar
problem, it can be inferred that the effects of
cyclization depend on the overall structure of the
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inhibitor and cannot be generalized as having
positive or negative effects on inhibitory potency.
Compound 5 is another reversible inhibitor. The
aromatic residues that interact with the S4 region
of caspase-1 are separated by several methylene
groups. Cleverly, this SMI was optimized
through a fragment-assembly approach. First, a
P1 fragment that contained a terminal thiol was
bound to the active site; then, a disulfide bond
formed with an analogously modified P3/P4
fragment only if this fragment was able to bind to
the respective region of caspase-1.19 Although
neither fragment inhibits the protease by itself, a
submicromolar potency is observed when they
are combined. In the final structure of 5, the
disulfide bond is replaced with a hydrocarbon
skeleton. The SMI shows appreciable inhibition
of both caspases-1 and -5 with respective Ki
values of 0.016 and 2.03 µM and thus can be
classified as a pan-inhibitor.
The compatibility of an inhibitor with two or
more of the inflammatory caspases is no small
feat. Indeed, compounds 1-4 have not been
reported to have any effect on the activity of
caspases-4 and -5, making compound 5 an
attractive design for a reversible inhibitor. Broad
inhibition of caspases-1, -4, and -5 is preferred,
given that all three are influential in the
production of IL-1β. By inhibiting two or more
with one inhibitor, this SMI is more likely to
show successful results in clinical trials.
However, this challenge becomes increasingly
difficult upon considering that the inhibitor must
also be caspase-specific. If the SMI is
promiscuous with all catalytic thiolates, including
the apoptotic caspases, or attractive to other
cellular nucleophiles, its utility will be
compromised.
Unlike 1-5, compound 6 is an irreversible
inhibitor. This SMI is derived from isoquinoline1,3,4-trione, which acts as the leaving group upon
trapping the catalytic residue of caspase-1. Broad
inhibition of the inflammatory caspases has been
observed with the SMI, but it is selective for this
family and does not act as a general protease
inhibitor.16 Remarkably, 6 does not possess the
essential aspartic residue at P1. The lack of this
residue leads to slow binding to the aspartatespecific caspases, but since the binding is

Published by Via Sapientiae, 2021

irreversible, it cannot be undone after doing so.
The SMI also shows acceptable cellular
penetration due to its largely hydrophobic
scaffold. Structures like 5 and 6, which link the
P1 and P4 regions via methylene groups, may be
useful in broadly inhibiting the caspase family.
Currently, it does not appear that analogs of these
structures have been extensively pursued.
Therefore, optimization of these scaffolds could
afford promising candidates.
As previously stated, it is not uncommon for the
prime side of a caspase inhibitor to be missing or
simply used as a leaving group. Compounds 7
and 8 are unique in that they are inhibitors that
were developed by optimizing the prime side
interactions with caspase-1.6 Both are remarkably
potent, recording Ki values of 2 and 1 pM,
respectively. The former is an acyloxyalkyl
ketone that possesses a bulky hydrophobic and
aromatic prime side, which anchors the SMI to
the protease’s hydrophobic interior. SMI 7 also
exhibits bimodal inhibition, decreasing caspase-1
activity via reversible and irreversible inhibition.
Interestingly, SAR studies revealed that
optimizing the potency of the ester favored the
irreversible mechanism. Compound 8 is a
hydroxamate analog that exhibits only reversible
inhibition regardless of the potency.
Although diverse in structure, compounds 1-8
can be described using the general structure of
caspase-1 inhibitors (with the exception of 6).
They contain an aspartate residue at the P1
position and have modifications in the P2-P4 and
prime side regions. Recently, there has been a
focus on caspase-1 SMIs that significantly
deviate from the traditional structure. Indeed,
inhibitors that occupy similar spatial areas as 1
and 2 but are not peptidomimetic are attractive
candidates, given the poor biostability associated
with hydrolysable species. Compounds 9 and 10
are examples of such candidates, as neither have
an aspartate residue nor many enticing peptide
bonds that can allure cellular nucleophiles. SMI 9
was optimized for the active site through the
variation of the substituents on the
diaminopyrimidine derivative.9 No covalent
interactions with Cys285 were reported despite
the binding of 9 to the active site. Similarly, LCMS analysis of caspase-1 after treatment with
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compound 10 did not suggest any covalent
interactions either.10 Notably, this compound
inhibits caspase-1 (Ki = 48 nM) even with the
addition of excess substrate14, suggesting that it
likely operates via an allosteric mechanism.
Though allosteric inhibitors of caspase-1 do exist,
they are rare.
Compounds 9 and 10 likely offer insight into the
future structure of a successful drug candidate for
caspase-1 inhibition. These SMIs have a scaffold
that should be able to readily permeate the
cellular membrane and evade the attention of
cellular nucleophiles. Therefore, optimizing 9
and 10 and further elucidating their mechanisms
of inhibition are useful research targets.
INHIBITORS OF CASPASES-4 AND -5
Of the SMIs discussed so far, most have not been
pan-caspase inhibitors. With the exception of 5
and 6, the target of inhibition has been
exclusively caspase-1. Impeding the activity of
this enzyme has received significantly more
attention than its inflammatory counterparts,
caspases-4 and -5. The reason for this trend is that
the pathway that converts pro-IL-1β into its
active cytokine form is the prototypical innate
immune response. Additionally, the crystallized
structure of caspase-4 has only recently been
deposited on online databases, limiting the use of
docking studies to model interactions. The
crystallized structure of caspase-5 remains
outstanding; though, sequence alignment with

caspase-1 has been performed to predict its native
form.
Both caspases-4 and -5 are known to activate the
NLRP3 inflammasome through the noncanonical
pathway and also regulate the secretion of
another cytokine, IL-1α.26 Therefore, from a
therapeutic perspective, it may be impractical to
decrease inflammation by only inhibiting
caspase-1. Fortunately, the genetic sequence
among the inflammatory caspases is highly
conserved,
which
allows
for
shared
characteristics among putative SMIs, such as
aspartate-specificity and hydrophobicity in the S4
region.25
When caspases-4 and -5 were discovered, it was
ascertained that the proteases must have similar
substrate preferences due to pan-inhibition via the
cowpox virus-derived inhibitor, CrmA.11 Shortly
after, peptidic SMIs that are analogous to the
putative caspase-1 inhibitor Ac-YVAD-CHO
were identified. Compounds 11 and 12 are
inhibitors of caspases-4 and -5, respectively;
though, both show a certain degree of paninhibition (Figure 5). The structures of these
SMIs are Z-LEVD-FMK and Z-WEHD-FMK.
These SMIs diffuse across the lipid bilayer of the
cell membrane more easily than 1 and 2 due to the
esterification of the hydrophilic carboxy groups
on glutamate and aspartate. It should be noted that
peptidic aldehyde versions of 11 and 12, like 1
and 2, have also been identified as possessing
inhibitory effects on their respective caspase.12 It
is not surprising that, like caspase-1, the activity

Figure 5. Known inhibitors of caspases-4 and -5.
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of caspases-4 and -5 can be suppressed by species
that closely mimic a natural peptide. The active
sites are highly conserved and thus readily bind
to these structures. Such a luxury comes at the
cost of biostability and other problems, as
previously stated.
SMIs like 13 and 14 are not as obvious as the
substrate-based 11 and 12 but are remarkably
promising allosteric prospects. Caspases,
including both the inflammatory and apoptotic
players, have a cavity at the dimeric interface of
the heterodimers, which is located 15 Å away
from the active site. In regard to caspase-1,
Cys331 is found within this region and can be
allosterically trapped.23 When such process
occurs, a salt bridge between Arg286 and Glu390
that aligns the active site for catalysis is broken.
Fortunately, all three of these residues are
conserved throughout the caspase family,
denoting a common regulatory mechanism. It
should be noted that this mechanism is likely
responsible for the allosteric inhibition of
caspase-1 by 10.
Compound 13 is a naphthyl-thiazole-containing
SMI. Upon treatment of caspase-5 with 13, both
the turnover rate and binding affinity of the
substrate decreased. Such an observation is
consistent with a mechanism of allosteric
regulation. This SMI therefore likely acts as a
negative regulator molecule and causes a
conformational change in caspase-5.7 No effects
were observed on caspase-1, indicating an
appreciable selectivity. Thus far, SMIs 1-13 have
shown no or partial pan-inhibition of the
inflammatory caspases. Compound 14 deviates
from this trend, demonstrating Ki values of 16, 8,
and 16 nM for caspases-1, -4, and -5,
respectively.10 This triamino pyrimidine
derivative is an alluring prospect for future
optimization.

successful therapeutic candidate will not closely
mirror a natural peptide. While these SMIs are
useful for research purposes, they are not viable
pharmaceutic candidates due to a lack of stability
and selectivity. Therefore, SMIs that attract less
undesirable side reactions will likely be critical to
surpassing clinical trials. This hurdle favors
allosteric regulators, like compounds 10, 13, and
14. The conserved dimer interface among the
caspases could allow for selective pan-inhibition
that would effectively shut off the innate immune
response, temporarily alleviating the pain of the
discussed pathologies. Although further work
should be performed to optimize the allosteric
regulators, a challenge will be the compact pocket
of the dimer interface that may limit the extent of
structural modifications.
Inhibitors of caspase-1 have been the focus of
recent research. While there are over onehundred known SMIs of caspase-1, there is a
small list for both caspases-4 and -5. As more
SMIs of these caspases are discovered,
optimization will be facilitated. Until recently,
little information has been available on public
databases regarding the quaternary structures of
these proteases. Although homology modeling is
useful for docking studies, it is not as helpful as a
crystallized model. Therefore, it stands to reason
that inhibitors or regulators of caspases-4 and -5
will become more available in the coming years.
With some good fortune, a therapeutic SMI of the
inflammatory caspases can be expected within
the next decade. Although the same was said a
decade prior, a focus on optimizing a nontraditional structure, like an allosteric regulator,
was not actively pursued at the time.

SUMMARY
The known inhibitors of caspases-1, -4, and -5
have evolved from solely substrate-based
molecules into less restricted peptidomimetic
structures and, recently, allosteric regulators. It is
thus clear from the trends in current research on
the inflammatory caspases that the eventual
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